| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5603557 | Heart Rhythm | 2016 | 6 Pages |
Abstract
Dofetilide remains a viable antiarrhythmic drug option in this challenging population. At 3 years, 49% remained on dofetilide. Close monitoring of renal function, concomitant medications, and corrected QT interval is required.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Iqbal MD, Sadeer G. MD, JoEllyn MD, Shubhayan MD, FHRS, David J. MD, FHRS, Colby MD, Ian H. MD, FHRS, Seshadri MBBS, FRCP(UK), PhD, Ira MD, Peter F. MD, FHRS,